Revascularization and clinical outcomes in the NASA post marketing registry versus the SWIFT and TREVO 2 trials
| Outcome | NASA registry (n=354) | SWIFT trial (n=58) | p Value | TREVO 2 trial (n=88) | p Value |
|---|---|---|---|---|---|
| TIMI ≥2 (n (%) or %) | 296 (83.3) | 83 | 0.9 | NA | NA |
| TICI ≥2a (n (%) or %) | 310 (87.5) | NA | NA | 85 | 0.5 |
| TICI ≥2b (n (%) or %) | 256 (72.5) | NA | NA | 68 | 0.4 |
| TICI 3 (n (%) or %) | 142 (40.2) | NA | NA | 14 | <0.001 |
| Rescue therapy (n (%) or %) | 91 (25.7) | 21 | 0.7 | 18 | 0.2 |
| Passes (n (%)) | |||||
| 1 | 172 (49) | ||||
| 2 | 94 (27) | ||||
| 3 | 64 (18) | ||||
| >3 passes (%) | 6.3 | ||||
| 4 in 14 (4.2) | |||||
| 5 in 7 (2.1) | |||||
| 9 in 1 (0.03) | |||||
| Mean (SD) | 1.9 (1.1) | 1.7 (0.9) | 0.13 | 2.4 (1.4) | 0.002 |
| Median (IQR) | 2 (1–2) | NA | NA | NA | NA |
| mRS ≤2 (n (%) or %) | 132/315 (42) | 37 | 0.4 | 40 | 0.5 |
| Death (n (%) or %) | 95/315 (30.2) | 17.2 | 0.05 | 29 | 1 |
| sICH (n (%) or %) | 35/352 (9.9) | 2 | 0.05 | 4 | 0.1 |
mRS, modified Rankin scale; NASA, North American Solitaire Acute Stroke registry; sICH, symptomatic intracranial hemorrhage; SWIFT trial, Solitaire with the Intention for Thrombectomy trial; TICI, Treatment in Cerebral Infarction; TIMI, Thrombolysis in Myocardial Ischemia; TREVO 2 trial, Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusions in acute ischemic stroke trial.